Inflarx presents new analysis of panamo phase iii trial in severe covid-19 at ats 2024 showing potential synergy with vilobelimab when used in combination with other immunomodulators

Jena, germany, may 21, 2024 (globe newswire) -- inflarx n.v. (nasdaq: ifrx), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the american thoracic society (ats) 2024 international conference that is being held from may 17-22, 2024 in san diego.
ATS Ratings Summary
ATS Quant Ranking